amlodipine has been researched along with Hypertension, Essential in 62 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its clinical efficacy for essential hypertension (EH)." | 9.69 | Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension. ( Chen, Y; Lu, X; Sun, N; Wang, H; Wang, L; Xi, Y; Yang, F, 2023) |
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 9.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| "Our study indicated that olmesartan and amlodipine could improve endothelial function in patients with essential hypertension in different manners, suppression of vascular inflammation, and decrease in blood pressure variability, respectively." | 9.69 | Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation. ( Abe, T; Bekki, M; Fukumoto, Y; Honda, A; Igata, S; Kurata, S; Maeda-Ogata, S; Matsui, T; Nishino, Y; Sugiyama, Y; Tahara, A; Tahara, N; Yamagishi, SI, 2023) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 9.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "We investigated changes in blood pressure (BP) and metabolic adverse effects, especially elevation of uric acid (UA), after treatment with a thiazide-like diuretic (TD) in patients with essential hypertension." | 9.34 | Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension. ( Hanada, H; Higaki, J; Higashiura, K; Horio, T; Hosomi, N; Igase, M; Ishimitsu, T; Iwashima, Y; Kamide, K; Katabuchi, R; Kato, J; Kawano, Y; Kojima, S; Komai, N; Matsuura, H; Miki, T; Miwa, Y; Miyata, T; Morimoto, S; Nakahama, H; Nakahashi, T; Nakamura, S; Ohta, Y; Oukura, T; Rakugi, H; Sasaguri, T; Sase, K; Shimamoto, K; Shinagawa, T; Soma, M; Sugimoto, K; Takeda, K; Takiuchi, S; Tomohiro Katsuya, T; Tsuchihashi, T; Ueno, M; Yoshihara, F, 2020) |
| "The aim of this study was to assess the effects of irbesartan alone and combined with amlodipine, efonidipine, or trichlormethiazide on blood pressure (BP) and urinary albumin (UA) excretion in hypertensive patients with microalbuminuria (30≤UA/creatinine (Cr) ratio [UACR] <300 mg/g Cr) and upper-normal microalbuminuria (10≤UACR<30 mg/g Cr)." | 9.27 | Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. ( Asayama, K; Hanazawa, T; Hosaka, M; Imai, Y; Inoue, R; Obara, T; Ohkubo, T; Satoh, M; Watabe, D, 2018) |
| "This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA." | 9.27 | Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018) |
| "The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia." | 9.24 | A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. ( Cha, DH; Choi, JH; Choi, JY; Choi, KJ; Choi, SW; Hong, TJ; Jung, HO; Kim, KH; Kim, SM; Kim, SY; Kim, WS; Lee, HY; Lee, KJ; Oh, JH; Park, DG; Park, SW; Park, TH; Rha, SW; Rhee, MY; Ryu, DR; Shim, J; Song, PS; Yoo, BS, 2017) |
| " The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension." | 9.24 | Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. ( Ahn, T; Chae, SC; Cho, EJ; Cho, JH; Choi, JY; Chung, WB; Hong, TJ; Ihm, SH; Jeon, HK; Jeong, MH; Kim, CJ; Kim, WS; Kim, YK; Lee, HY; Lee, JH; Nam, CW; Park, JI; Park, SM; Shin, ES; Sohn, IS; Yang, TH; Yoon, JH; Youn, HJ, 2017) |
| "The goal of this study was to evaluate whether the blood pressure-lowering efficacy of fimasartan/amlodipine combination therapy was superior to that of fimasartan monotherapy after 8 weeks of treatment in patients with hypertension who had failed to respond adequately to fimasartan monotherapy." | 9.22 | A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. ( Cha, KS; Chae, SC; Chun, KJ; Ihm, SH; Il Kim, D; Jeong, JO; Joo, SJ; Kim, CH; Kim, DS; Kim, JJ; Kim, KH; Kim, KI; Kim, MH; Kim, YJ; Nam, CW; Park, S; Park, SM; Rhee, MY; Seo, HS; Shin, ES; Shin, J; Shin, MS; Sung, KC; Yoo, BS; Youn, HJ, 2016) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 9.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 9.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation." | 9.20 | A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. ( Ahn, T; Ahn, Y; Bae Park, J; Cho, EJ; Choi, DJ; Chull Chae, S; Chun, KJ; Han, KR; Hyon, MS; Jeon, ES; Jeong, JO; Joo, SJ; Kim, DI; Kim, DS; Kim, JJ; Kim, KS; Kim, YJ; Kwan, J; Lee, HY; Oh, SK; Park, JS; Rhee, MY; Seog Seo, H; Shin, JH; Sung, KC; Yoo, BS; Youn, HJ, 2015) |
| "Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery." | 9.19 | [A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014) |
| "The objective of this study was to compare the efficacy and tolerability of the FDC of azilsartan (AZI) and amlodipine besylate (AML) with those of AZI monotherapy and AML monotherapy in Japanese patients with grade 1 to 2 essential hypertension." | 9.19 | Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension. ( Kagawa, T; Nakata, E; Rakugi, H; Sasaki, E, 2014) |
| "In patients who were previously uncontrolled on CCB monotherapy or untreated with grade 2 or 3 hypertension, single-pill combination indapamide SR/amlodipine reduced BP effectively--especially SBP--over 45 days, and was safe and well tolerated." | 9.19 | Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. ( Gujral, VK; Hiremath, J; Jadhav, U; Namjoshi, DJ; Safar, M; Shamanna, P; Siraj, M; Tripathi, KK, 2014) |
| "The objective of this study was to investigate the efficacy of the fixed-dose combination olmesartan/amlodipine 40/10 mg in patients with moderate essential hypertension not controlled on candesartan 32 mg." | 9.19 | Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2014) |
| "A direct switch of candesartan to the fixed-dose combination olmesartan/amlodipine in uncontrolled hypertension is a frequent clinical requirement but is not covered by current labeling." | 9.17 | Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2013) |
| " In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calcium channel blocker on the vWf levels and N/L ratio in patients with essential hypertension." | 9.17 | The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. ( Arslan, Z; Balta, S; Bozoglu, E; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Kocak, N; Kurt, O; Naharci, I; Sarlak, H; Seyit Ahmet, AY, 2013) |
| "To evaluate the effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension." | 9.17 | [The effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension]. ( Hu, DY; Jia, T; Yu, JM; Zhan, YQ; Zhang, LJ, 2013) |
| "Although amlodipine is recommended as the first-line therapy for the treatment of hypertension, its use is limited by its potential side effects." | 8.12 | Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study. ( Ahn, JH; Ahn, KT; Choi, WG; Jung, IH; Kang, SH; Kim, DK; Kim, SS; Lee, JH; Lee, KH; Na, JO; Park, SD; Seo, J, 2022) |
| "The analysis will evaluate the efficiency and level of safeness of levamlodipine besylate combined treatment for essential hypertension." | 8.12 | Clinical assessment of levamlodipine besylate combination therapy for essential hypertension: A protocol for systematic review and meta-analysis. ( Dai, GY; Zhu, YH, 2022) |
| "A total of 108 mild-to-moderate essential hypertension patients in Chinese Han nationality were treated with amlodipine for 8 weeks at a dosage of 5 mg/d." | 7.83 | [Association between gene polymorphism of calcium/calmodulin-dependent kinase 4 and efficacy of amlodipine in the treatment of hypertension in Chinese Han nationality]. ( Chen, Y; Liu, L; Liu, Y; Luo, Y; Yang, L; Yao, J; Zhong, G, 2016) |
| "to assess efficacy of a fixed combination of perindopril arginine and amlodipine besylate in the treatment of hypertensive patients with chronic heart failure (CHF) and signs of chronic kidney disease (CKD)." | 7.81 | [Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination]. ( Borovkov, NN; Borovkova, NJ; Kovaleva, GV; Kuznecova, TE, 2015) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 7.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| " During follow-up, the OA dosage is adjusted according to the ABPM and OBPM results." | 7.30 | The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open- ( Chen, X; Jia, S; Li, X; Liao, H; Liu, K; Liu, X; Meng, Q; Shi, R; Sun, L; Wang, S; Wang, Z; Xu, M; Ye, R; Zhang, X; Zhang, Z, 2023) |
| "Most adverse events (AEs) were mild or moderate in intensity, and no deaths or treatment-related serious AEs were reported." | 6.87 | A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension. ( Nishiyama, Y; Rakugi, H; Sano, Y; Shimizu, K; Umeda, Y, 2018) |
| " The adverse events (AEs) during both treatment periods were generally mild." | 6.84 | The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension. ( Higaki, J; Ikeda, H; Komuro, I; Kuroki, D; Nishimura, S; Ogihara, T; Shiki, K; Taniguchi, A; Ugai, H, 2017) |
| " Both treatment regimens were well tolerated regarding adverse events or laboratory testing." | 6.84 | Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. ( Amodeo, C; Asmar, R; Brzozowska-Villatte, R; de Champvallins, M; Mourad, JJ, 2017) |
| " There were no differences between 4 dosing regimens in laboratory and clinical parameters of safety and tolerability." | 6.79 | [Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension]. ( Kobalava, ZhD, 2014) |
| " Population pharmacokinetic analyses were performed on data which were collected prospectively from 60 Chinese patients with mild to moderate essential hypertension [age range 40-74 years, males (n = 31), females (n = 29)] receiving oral racemic amlodipine for 4 weeks." | 6.79 | ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. ( Barrett, JS; Guo, CX; Hua, Y; Huang, ZJ; Pei, Q; Wang, JL; Yang, GP; Yuan, H; Zhang, WL; Zhou, HH; Zuo, XC, 2014) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 6.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Our study indicated that olmesartan and amlodipine could improve endothelial function in patients with essential hypertension in different manners, suppression of vascular inflammation, and decrease in blood pressure variability, respectively." | 5.69 | Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation. ( Abe, T; Bekki, M; Fukumoto, Y; Honda, A; Igata, S; Kurata, S; Maeda-Ogata, S; Matsui, T; Nishino, Y; Sugiyama, Y; Tahara, A; Tahara, N; Yamagishi, SI, 2023) |
| "Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its clinical efficacy for essential hypertension (EH)." | 5.69 | Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension. ( Chen, Y; Lu, X; Sun, N; Wang, H; Wang, L; Xi, Y; Yang, F, 2023) |
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 5.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| "Eighty-six elderly patients with essential hypertension were randomized into a control group (oral Amlodipine Besylate Tablets) and an observation group (oral Amlodipine Besylate Tablets + HMG-CoA reductase inhibitor atorvastatin calcium)." | 5.69 | Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway. ( Fan, H; Liu, Z; Luo, W; Ouyang, F; Tang, L; Yan, Y; Yang, H; Yuan, W, 2023) |
| " Serious adverse events (SAEs) and unexpected adverse events (UAEs) occurred in 0." | 5.56 | Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Essential Hypertension (RESOLVE): A Large, Observational, Retrospective, Cohort Study. ( Park, SJ; Rhee, SJ, 2020) |
| "The aim of this clinical trial was to assess the efficacy and safety of low-dose triple combinations of amlodipine, telmisartan, and chlorthalidone in patients with essential hypertension." | 5.51 | Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. ( Ahn, JC; Cho, EJ; Han, SH; Kang, SM; Kim, KH; Kim, KI; Kim, SY; Kim, W; Kim, YJ; Park, CG; Park, SJ; Park, SM; Shin, J; Shin, JH; Sohn, IS; Sung, JH; Sung, KC, 2022) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 5.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "To evaluate, in patients with type 2 diabetes and hypertension, the effects of 6 months treatment with canagliflozin, or perindopril, an angiotensin converting enzyme inhibitor, on central BP and carotid-femoral pulse wave velocity (cfPWV)." | 5.51 | Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. ( Ramirez, AJ; Sanchez, MJ; Sanchez, RA, 2019) |
| "We investigated changes in blood pressure (BP) and metabolic adverse effects, especially elevation of uric acid (UA), after treatment with a thiazide-like diuretic (TD) in patients with essential hypertension." | 5.34 | Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension. ( Hanada, H; Higaki, J; Higashiura, K; Horio, T; Hosomi, N; Igase, M; Ishimitsu, T; Iwashima, Y; Kamide, K; Katabuchi, R; Kato, J; Kawano, Y; Kojima, S; Komai, N; Matsuura, H; Miki, T; Miwa, Y; Miyata, T; Morimoto, S; Nakahama, H; Nakahashi, T; Nakamura, S; Ohta, Y; Oukura, T; Rakugi, H; Sasaguri, T; Sase, K; Shimamoto, K; Shinagawa, T; Soma, M; Sugimoto, K; Takeda, K; Takiuchi, S; Tomohiro Katsuya, T; Tsuchihashi, T; Ueno, M; Yoshihara, F, 2020) |
| " A total of 121 participants with type 2 diabetes and uncontrolled essential hypertension, who were receiving medium doses of amlodipine (5 mg/day) and ARB, were enrolled." | 5.30 | Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study. ( Fukushima, M; Hoshino, F; Imaizumi, S; Kusumoto, T; Matsunaga, A; Miura, SI; Morito, N; Nagata, Y; Norimatsu, K; Ogawa, M; Sako, H; Saku, K; Shiga, Y; Shimono, D; Shirotani, T; Sugihara, H; Tanigawa, H; Uehara, Y; Yahiro, E, 2019) |
| "The aim of this study was to assess the effects of irbesartan alone and combined with amlodipine, efonidipine, or trichlormethiazide on blood pressure (BP) and urinary albumin (UA) excretion in hypertensive patients with microalbuminuria (30≤UA/creatinine (Cr) ratio [UACR] <300 mg/g Cr) and upper-normal microalbuminuria (10≤UACR<30 mg/g Cr)." | 5.27 | Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. ( Asayama, K; Hanazawa, T; Hosaka, M; Imai, Y; Inoue, R; Obara, T; Ohkubo, T; Satoh, M; Watabe, D, 2018) |
| "This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA." | 5.27 | Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018) |
| " The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension." | 5.24 | Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. ( Ahn, T; Chae, SC; Cho, EJ; Cho, JH; Choi, JY; Chung, WB; Hong, TJ; Ihm, SH; Jeon, HK; Jeong, MH; Kim, CJ; Kim, WS; Kim, YK; Lee, HY; Lee, JH; Nam, CW; Park, JI; Park, SM; Shin, ES; Sohn, IS; Yang, TH; Yoon, JH; Youn, HJ, 2017) |
| "The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia." | 5.24 | A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. ( Cha, DH; Choi, JH; Choi, JY; Choi, KJ; Choi, SW; Hong, TJ; Jung, HO; Kim, KH; Kim, SM; Kim, SY; Kim, WS; Lee, HY; Lee, KJ; Oh, JH; Park, DG; Park, SW; Park, TH; Rha, SW; Rhee, MY; Ryu, DR; Shim, J; Song, PS; Yoo, BS, 2017) |
| "The goal of this study was to evaluate whether the blood pressure-lowering efficacy of fimasartan/amlodipine combination therapy was superior to that of fimasartan monotherapy after 8 weeks of treatment in patients with hypertension who had failed to respond adequately to fimasartan monotherapy." | 5.22 | A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. ( Cha, KS; Chae, SC; Chun, KJ; Ihm, SH; Il Kim, D; Jeong, JO; Joo, SJ; Kim, CH; Kim, DS; Kim, JJ; Kim, KH; Kim, KI; Kim, MH; Kim, YJ; Nam, CW; Park, S; Park, SM; Rhee, MY; Seo, HS; Shin, ES; Shin, J; Shin, MS; Sung, KC; Yoo, BS; Youn, HJ, 2016) |
| "The combination olmesartan/amlodipine is safe, well tolerated, and as effective as the combination of perindopril/amlodipine in the control of essential hypertension in patients with diabetes mellitus." | 5.22 | Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. ( Pichler, G; Redon, J, 2016) |
| "To assess the blood pressure-lowering efficacy and tolerability of perindopril/amlodipine fixed-dose combinations in Chinese patients with mild-to-moderate essential hypertension not adequately controlled with monotherapy alone." | 5.22 | Efficacy and Safety of Fixed-Dose Perindopril Arginine/Amlodipine in Hypertensive Patients Not Adequately Controlled with Amlodipine 5 mg or Perindopril tert-Butylamine 4 mg Monotherapy. ( Hu, D; Huang, J; Liao, Y; Sun, Y; Yang, K; Zhao, R, 2016) |
| "The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation." | 5.20 | A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. ( Ahn, T; Ahn, Y; Bae Park, J; Cho, EJ; Choi, DJ; Chull Chae, S; Chun, KJ; Han, KR; Hyon, MS; Jeon, ES; Jeong, JO; Joo, SJ; Kim, DI; Kim, DS; Kim, JJ; Kim, KS; Kim, YJ; Kwan, J; Lee, HY; Oh, SK; Park, JS; Rhee, MY; Seog Seo, H; Shin, JH; Sung, KC; Yoo, BS; Youn, HJ, 2015) |
| " The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol,hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order." | 5.20 | Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. ( Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Donner, KM; Frau, F; Glorioso, N; Glorioso, V; Gong, Y; Gums, JG; Hiltunen, TP; Johnson, JA; Kontula, KK; Ripatti, S; Saarela, J; Salvi, E; Sarin, AP; Turner, ST; Zaninello, R, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 5.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 5.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "In patients who were previously uncontrolled on CCB monotherapy or untreated with grade 2 or 3 hypertension, single-pill combination indapamide SR/amlodipine reduced BP effectively--especially SBP--over 45 days, and was safe and well tolerated." | 5.19 | Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. ( Gujral, VK; Hiremath, J; Jadhav, U; Namjoshi, DJ; Safar, M; Shamanna, P; Siraj, M; Tripathi, KK, 2014) |
| "The objective of this study was to compare the efficacy and tolerability of the FDC of azilsartan (AZI) and amlodipine besylate (AML) with those of AZI monotherapy and AML monotherapy in Japanese patients with grade 1 to 2 essential hypertension." | 5.19 | Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension. ( Kagawa, T; Nakata, E; Rakugi, H; Sasaki, E, 2014) |
| "The objective of this study was to investigate the efficacy of the fixed-dose combination olmesartan/amlodipine 40/10 mg in patients with moderate essential hypertension not controlled on candesartan 32 mg." | 5.19 | Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2014) |
| "Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery." | 5.19 | [A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014) |
| " In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calcium channel blocker on the vWf levels and N/L ratio in patients with essential hypertension." | 5.17 | The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. ( Arslan, Z; Balta, S; Bozoglu, E; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Kocak, N; Kurt, O; Naharci, I; Sarlak, H; Seyit Ahmet, AY, 2013) |
| "To evaluate the effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension." | 5.17 | [The effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension]. ( Hu, DY; Jia, T; Yu, JM; Zhan, YQ; Zhang, LJ, 2013) |
| "Administering amlodipine in 2 divided doses was not associated with increased trough plasma amlodipine concentrations, reduced arterial stiffness, or improved BP control over a 24-hour period in patients with essential hypertension." | 5.17 | Effects of dividing amlodipine daily doses on trough drug concentrations and blood pressure control over a 24-hour period. ( Higaki, J; Irita, J; Masanori, J; Miyoshi, K; Nagao, T; Okura, T, 2013) |
| "A direct switch of candesartan to the fixed-dose combination olmesartan/amlodipine in uncontrolled hypertension is a frequent clinical requirement but is not covered by current labeling." | 5.17 | Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2013) |
| " In this study, we investigated the effects of valsartan and amlodipine on the lipid profile in patients with newly diagnosed essential hypertension." | 5.17 | An additional LDL-lowering effect of amlodipine; not only an antihypertensive? ( Akhan, M; Arslan, E; Arslan, Z; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Saglam, K; Sarlak, H, 2013) |
| "The analysis will evaluate the efficiency and level of safeness of levamlodipine besylate combined treatment for essential hypertension." | 4.12 | Clinical assessment of levamlodipine besylate combination therapy for essential hypertension: A protocol for systematic review and meta-analysis. ( Dai, GY; Zhu, YH, 2022) |
| "Although amlodipine is recommended as the first-line therapy for the treatment of hypertension, its use is limited by its potential side effects." | 4.12 | Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study. ( Ahn, JH; Ahn, KT; Choi, WG; Jung, IH; Kang, SH; Kim, DK; Kim, SS; Lee, JH; Lee, KH; Na, JO; Park, SD; Seo, J, 2022) |
| "These data suggest that lisinopril/lisinopril + hydrochlorothiazide, losartan/losartan + hydrochlorothiazide and valsartan/valsartan + hydrochlorothiazide alone or in combination with amlodipine are equally effective and well tolerated for the reduction of both systolic and diastolic blood pressure and improve arterial stiffness in patients with essential hypertension." | 3.91 | Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. ( Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019) |
| "We found that a fixed combination of perindopril/amlodipine is effective in controlling BP in patients with essential hypertension, with older age, male gender, and diabetes mellitus being independent risk factors for less BP control." | 3.83 | The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study. ( Abdelhady, A; Albow, A; Khader, S; Sinnuqrut, S, 2016) |
| " We used pupillometry to evaluate the effects of the calcium channel blockers azelnidipine (AZ) and amlodipine (AM) on changes in autonomic nervous activity induced by isometric exercise in patients with hypertension." | 3.83 | Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients. ( Hano, T; Iwane, N; Kawabe, T; Koike, Y; Nishihara, K, 2016) |
| "A total of 108 mild-to-moderate essential hypertension patients in Chinese Han nationality were treated with amlodipine for 8 weeks at a dosage of 5 mg/d." | 3.83 | [Association between gene polymorphism of calcium/calmodulin-dependent kinase 4 and efficacy of amlodipine in the treatment of hypertension in Chinese Han nationality]. ( Chen, Y; Liu, L; Liu, Y; Luo, Y; Yang, L; Yao, J; Zhong, G, 2016) |
| "to assess efficacy of a fixed combination of perindopril arginine and amlodipine besylate in the treatment of hypertensive patients with chronic heart failure (CHF) and signs of chronic kidney disease (CKD)." | 3.81 | [Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination]. ( Borovkov, NN; Borovkova, NJ; Kovaleva, GV; Kuznecova, TE, 2015) |
| "Aim of the METR study - to assess effect of antihypertensive therapy with fixed combination of angiotensin converting enzyme inhibitor lisinopril (10 mg) and calcium antagonist amlodipine (5 mg) on parameters of arterial wall stiffness and central hemodynamics in patients with stage I-II essential hypertension (EH) and functional class II-III ischemic heart disease." | 3.81 | [Stiffness of the Arterial Wall and Central Hemodynamics During Long-Term Combination Antihypertensive Therapy]. ( Glezer, MG; Prokofieva, EB, 2015) |
| "A European multi-center, prospective, 24-week, non-interventional study was conducted including 14,979 patients with essential hypertension and new treatment with olmesartan, amlodipine and hydrochlorothiazide as an FDC." | 3.80 | Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. ( Bramlage, P; Fronk, EM; Ketelhut, R; Schmieder, RE; Smolnik, R; Wolf, WP; Zemmrich, C, 2014) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 3.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| " During follow-up, the OA dosage is adjusted according to the ABPM and OBPM results." | 3.30 | The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open- ( Chen, X; Jia, S; Li, X; Liao, H; Liu, K; Liu, X; Meng, Q; Shi, R; Sun, L; Wang, S; Wang, Z; Xu, M; Ye, R; Zhang, X; Zhang, Z, 2023) |
| "Most adverse events (AEs) were mild or moderate in intensity, and no deaths or treatment-related serious AEs were reported." | 2.87 | A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension. ( Nishiyama, Y; Rakugi, H; Sano, Y; Shimizu, K; Umeda, Y, 2018) |
| " The adverse events (AEs) during both treatment periods were generally mild." | 2.84 | The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension. ( Higaki, J; Ikeda, H; Komuro, I; Kuroki, D; Nishimura, S; Ogihara, T; Shiki, K; Taniguchi, A; Ugai, H, 2017) |
| " Both treatment regimens were well tolerated regarding adverse events or laboratory testing." | 2.84 | Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. ( Amodeo, C; Asmar, R; Brzozowska-Villatte, R; de Champvallins, M; Mourad, JJ, 2017) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 2.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| " There were no differences between 4 dosing regimens in laboratory and clinical parameters of safety and tolerability." | 2.79 | [Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension]. ( Kobalava, ZhD, 2014) |
| " Population pharmacokinetic analyses were performed on data which were collected prospectively from 60 Chinese patients with mild to moderate essential hypertension [age range 40-74 years, males (n = 31), females (n = 29)] receiving oral racemic amlodipine for 4 weeks." | 2.79 | ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. ( Barrett, JS; Guo, CX; Hua, Y; Huang, ZJ; Pei, Q; Wang, JL; Yang, GP; Yuan, H; Zhang, WL; Zhou, HH; Zuo, XC, 2014) |
| " Serious adverse events (SAEs) and unexpected adverse events (UAEs) occurred in 0." | 1.56 | Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Essential Hypertension (RESOLVE): A Large, Observational, Retrospective, Cohort Study. ( Park, SJ; Rhee, SJ, 2020) |
| "To evaluate, in patients with type 2 diabetes and hypertension, the effects of 6 months treatment with canagliflozin, or perindopril, an angiotensin converting enzyme inhibitor, on central BP and carotid-femoral pulse wave velocity (cfPWV)." | 1.51 | Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril. ( Ramirez, AJ; Sanchez, MJ; Sanchez, RA, 2019) |
| "Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels." | 1.43 | Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 47 (75.81) | 24.3611 |
| 2020's | 15 (24.19) | 2.80 |
| Authors | Studies |
|---|---|
| Sarkar, G | 1 |
| Gaikwad, VB | 1 |
| Sharma, A | 2 |
| Halder, SK | 1 |
| Kumar, DA | 1 |
| Anand, J | 1 |
| Agrawal, S | 1 |
| Kumbhar, A | 1 |
| Kinholkar, B | 1 |
| Mathur, R | 1 |
| Doshi, M | 1 |
| Bachani, D | 1 |
| Mehta, S | 1 |
| Kim, DK | 1 |
| Ahn, JH | 2 |
| Lee, KH | 1 |
| Kang, SH | 1 |
| Kim, SS | 1 |
| Na, JO | 1 |
| Park, SD | 1 |
| Ahn, KT | 1 |
| Lee, JH | 3 |
| Jung, IH | 1 |
| Seo, J | 1 |
| Choi, WG | 1 |
| Dai, GY | 1 |
| Zhu, YH | 1 |
| Sung, KC | 4 |
| Sung, JH | 1 |
| Cho, EJ | 4 |
| Ahn, JC | 2 |
| Han, SH | 1 |
| Kim, W | 2 |
| Kim, KH | 3 |
| Sohn, IS | 2 |
| Shin, J | 3 |
| Kim, SY | 3 |
| Kim, KI | 2 |
| Kang, SM | 1 |
| Park, SJ | 2 |
| Kim, YJ | 3 |
| Shin, JH | 2 |
| Park, SM | 4 |
| Park, CG | 1 |
| Honda, A | 1 |
| Tahara, N | 1 |
| Tahara, A | 1 |
| Bekki, M | 1 |
| Maeda-Ogata, S | 1 |
| Sugiyama, Y | 2 |
| Igata, S | 1 |
| Nishino, Y | 1 |
| Matsui, T | 1 |
| Kurata, S | 1 |
| Abe, T | 1 |
| Yamagishi, SI | 1 |
| Fukumoto, Y | 1 |
| Wang, H | 1 |
| Xi, Y | 1 |
| Chen, Y | 2 |
| Wang, L | 1 |
| Yang, F | 1 |
| Lu, X | 1 |
| Sun, N | 1 |
| Kim, MC | 1 |
| Ahn, Y | 3 |
| Kim, MH | 3 |
| Hong, TJ | 4 |
| Rhee, MY | 5 |
| Kim, SH | 3 |
| Hong, SJ | 3 |
| Kim, H | 1 |
| Chae, IH | 2 |
| Kang, DH | 1 |
| Kim, BK | 1 |
| Kim, HS | 3 |
| Xie, M | 1 |
| Tang, T | 1 |
| Liang, H | 1 |
| Kim, YH | 1 |
| Chang, K | 1 |
| Choi, DJ | 2 |
| Kang, WC | 1 |
| Lee, N | 1 |
| Son, JW | 2 |
| Doh, JH | 1 |
| Kim, WS | 3 |
| Lim, SW | 1 |
| Hong, SP | 1 |
| Choi, SY | 1 |
| Hyon, MS | 3 |
| Hwang, JY | 1 |
| Kwon, K | 1 |
| Cha, KS | 2 |
| Ihm, SH | 3 |
| Yoo, BS | 6 |
| Yuan, W | 1 |
| Fan, H | 1 |
| Yang, H | 1 |
| Tang, L | 1 |
| Liu, Z | 1 |
| Ouyang, F | 1 |
| Luo, W | 1 |
| Yan, Y | 1 |
| Xu, M | 1 |
| Zhang, X | 1 |
| Ye, R | 1 |
| Liu, X | 2 |
| Sun, L | 1 |
| Jia, S | 1 |
| Zhang, Z | 1 |
| Li, X | 1 |
| Wang, Z | 1 |
| Liao, H | 1 |
| Shi, R | 2 |
| Liu, K | 2 |
| Wang, S | 1 |
| Meng, Q | 1 |
| Chen, X | 2 |
| Jatic, Z | 1 |
| Skopljak, A | 1 |
| Hebibovic, S | 1 |
| Sukalo, A | 1 |
| Rustempasic, E | 1 |
| Valjevac, A | 1 |
| Ohta, Y | 1 |
| Kamide, K | 1 |
| Hanada, H | 1 |
| Morimoto, S | 1 |
| Nakahashi, T | 1 |
| Takiuchi, S | 1 |
| Ishimitsu, T | 1 |
| Tsuchihashi, T | 3 |
| Soma, M | 1 |
| Tomohiro Katsuya, T | 1 |
| Sugimoto, K | 1 |
| Rakugi, H | 6 |
| Oukura, T | 1 |
| Higaki, J | 3 |
| Matsuura, H | 1 |
| Shinagawa, T | 1 |
| Miwa, Y | 1 |
| Sasaguri, T | 1 |
| Igase, M | 1 |
| Miki, T | 1 |
| Takeda, K | 1 |
| Higashiura, K | 1 |
| Shimamoto, K | 1 |
| Katabuchi, R | 1 |
| Ueno, M | 1 |
| Hosomi, N | 1 |
| Kato, J | 1 |
| Komai, N | 1 |
| Kojima, S | 1 |
| Sase, K | 1 |
| Iwashima, Y | 1 |
| Yoshihara, F | 1 |
| Horio, T | 1 |
| Nakamura, S | 1 |
| Nakahama, H | 1 |
| Miyata, T | 1 |
| Kawano, Y | 1 |
| Niushko, TY | 1 |
| Tarasiuk, OK | 1 |
| Sikalo, YK | 1 |
| Lee, JW | 1 |
| Choi, E | 1 |
| Youn, YJ | 1 |
| Ahn, SG | 1 |
| Ahn, MS | 1 |
| Kim, JY | 1 |
| Lee, SH | 1 |
| Yoon, J | 1 |
| Ryu, DR | 2 |
| Hong, KS | 1 |
| Rhee, SJ | 1 |
| Zhang, ZL | 2 |
| Zhu, MM | 1 |
| Li, HL | 2 |
| Shi, LH | 1 |
| Chen, XP | 2 |
| Luo, J | 1 |
| Zhao, JF | 1 |
| Kim, CJ | 1 |
| Ahn, T | 2 |
| Youn, HJ | 3 |
| Jeon, HK | 1 |
| Chung, WB | 1 |
| Chae, SC | 2 |
| Nam, CW | 3 |
| Choi, JY | 2 |
| Kim, YK | 1 |
| Lee, HY | 3 |
| Cho, JH | 1 |
| Shin, ES | 2 |
| Yoon, JH | 1 |
| Yang, TH | 2 |
| Jeong, MH | 1 |
| Park, JI | 1 |
| Choi, KJ | 1 |
| Cha, DH | 2 |
| Jung, HO | 1 |
| Choi, JH | 1 |
| Lee, KJ | 1 |
| Park, TH | 1 |
| Oh, JH | 1 |
| Kim, SM | 1 |
| Shim, J | 1 |
| Choi, SW | 1 |
| Park, DG | 1 |
| Song, PS | 1 |
| Rha, SW | 2 |
| Park, SW | 1 |
| Hosaka, M | 1 |
| Inoue, R | 1 |
| Satoh, M | 1 |
| Watabe, D | 1 |
| Hanazawa, T | 1 |
| Ohkubo, T | 1 |
| Asayama, K | 1 |
| Obara, T | 1 |
| Imai, Y | 1 |
| Shimizu, K | 2 |
| Nishiyama, Y | 2 |
| Sano, Y | 2 |
| Umeda, Y | 1 |
| Kinugawa, Y | 1 |
| Terashio, S | 1 |
| Oh, YS | 1 |
| Won, KH | 1 |
| Yoo, KD | 1 |
| Ahn, YK | 1 |
| Jang, JY | 1 |
| Cho, SK | 1 |
| Park, SH | 1 |
| Song, JM | 1 |
| Jeong, JO | 3 |
| Yoon, YW | 1 |
| Kim, BS | 1 |
| Cho, DK | 1 |
| Choi, YJ | 1 |
| Jeon, DW | 1 |
| Ramirez, AJ | 1 |
| Sanchez, MJ | 1 |
| Sanchez, RA | 1 |
| Imaizumi, S | 1 |
| Shiga, Y | 1 |
| Ogawa, M | 1 |
| Sako, H | 1 |
| Nagata, Y | 1 |
| Matsunaga, A | 1 |
| Shirotani, T | 1 |
| Hoshino, F | 1 |
| Yahiro, E | 1 |
| Uehara, Y | 1 |
| Morito, N | 1 |
| Tanigawa, H | 1 |
| Shimono, D | 1 |
| Fukushima, M | 1 |
| Sugihara, H | 1 |
| Norimatsu, K | 1 |
| Kusumoto, T | 1 |
| Saku, K | 1 |
| Miura, SI | 1 |
| Dominiczak, AF | 1 |
| de Champvallins, M | 2 |
| Brzozowska-Villatte, R | 2 |
| Asmar, R | 2 |
| Hiremath, JS | 1 |
| Chokalingam, K | 1 |
| Mathan, G | 1 |
| Reddy, PNC | 1 |
| Dhawan, S | 1 |
| Toppo, A | 1 |
| Jia, T | 1 |
| Zhang, LJ | 1 |
| Zhan, YQ | 1 |
| Yu, JM | 1 |
| Hu, DY | 1 |
| Miyoshi, K | 1 |
| Okura, T | 1 |
| Nagao, T | 1 |
| Masanori, J | 1 |
| Irita, J | 1 |
| Zemmrich, C | 3 |
| Lüders, S | 2 |
| Gansz, A | 2 |
| Sturm, CD | 2 |
| Fimmers, R | 2 |
| Nadal, J | 2 |
| Schmieder, RE | 3 |
| Schrader, J | 2 |
| Bramlage, P | 3 |
| Zuo, XC | 1 |
| Zhang, WL | 1 |
| Yuan, H | 1 |
| Barrett, JS | 1 |
| Hua, Y | 1 |
| Huang, ZJ | 1 |
| Zhou, HH | 1 |
| Pei, Q | 1 |
| Guo, CX | 1 |
| Wang, JL | 1 |
| Yang, GP | 2 |
| Fang, H | 1 |
| Chen, W | 1 |
| Xu, W | 1 |
| Jadhav, U | 1 |
| Hiremath, J | 1 |
| Namjoshi, DJ | 1 |
| Gujral, VK | 1 |
| Tripathi, KK | 1 |
| Siraj, M | 1 |
| Shamanna, P | 1 |
| Safar, M | 1 |
| Ketelhut, R | 1 |
| Fronk, EM | 1 |
| Wolf, WP | 1 |
| Smolnik, R | 1 |
| Nakata, E | 1 |
| Sasaki, E | 1 |
| Kagawa, T | 1 |
| Inomata, J | 1 |
| Murai, H | 1 |
| Kaneko, S | 1 |
| Hamaoka, T | 1 |
| Ikeda, T | 1 |
| Kobayashi, D | 1 |
| Usui, S | 1 |
| Furusho, H | 1 |
| Takata, S | 1 |
| Takamura, M | 1 |
| Kobalava, ZhD | 1 |
| Ripley, DP | 1 |
| Negrou, K | 1 |
| Oliver, JJ | 1 |
| Worthy, G | 1 |
| Struthers, AD | 1 |
| Plein, S | 1 |
| Greenwood, JP | 1 |
| Shimada, K | 2 |
| Numaguchi, H | 2 |
| Nishida, C | 2 |
| Yamaguchi, H | 2 |
| Shirakawa, M | 2 |
| Azuma, K | 2 |
| Fujita, KP | 2 |
| Celık, T | 3 |
| Balta, S | 3 |
| Karaman, M | 3 |
| Ahmet Ay, S | 1 |
| Demırkol, S | 3 |
| Ozturk, C | 1 |
| Dınc, M | 1 |
| Unal, HU | 1 |
| Yılmaz, MI | 1 |
| Kılıc, S | 1 |
| Kurt, G | 1 |
| Tas, A | 1 |
| Iyısoy, A | 1 |
| Quartı-Trevano, F | 1 |
| Fıcı, F | 1 |
| Grassı, G | 1 |
| Galeeva, ZM | 1 |
| Galiavich, AS | 1 |
| Hiltunen, TP | 1 |
| Donner, KM | 1 |
| Sarin, AP | 1 |
| Saarela, J | 1 |
| Ripatti, S | 1 |
| Chapman, AB | 1 |
| Gums, JG | 1 |
| Gong, Y | 1 |
| Cooper-DeHoff, RM | 1 |
| Frau, F | 1 |
| Glorioso, V | 1 |
| Zaninello, R | 1 |
| Salvi, E | 1 |
| Glorioso, N | 1 |
| Boerwinkle, E | 1 |
| Turner, ST | 1 |
| Johnson, JA | 1 |
| Kontula, KK | 1 |
| Czarnecka, D | 1 |
| Koch, EM | 1 |
| Gottwald-Hostalek, U | 1 |
| Chull Chae, S | 1 |
| Seog Seo, H | 1 |
| Kim, KS | 1 |
| Kim, JJ | 2 |
| Chun, KJ | 2 |
| Park, JS | 1 |
| Oh, SK | 1 |
| Kim, DS | 2 |
| Kwan, J | 1 |
| Bae Park, J | 1 |
| Han, KR | 1 |
| Kim, DI | 1 |
| Joo, SJ | 2 |
| Jeon, ES | 1 |
| Prokofieva, EB | 1 |
| Glezer, MG | 1 |
| Borovkova, NJ | 1 |
| Kuznecova, TE | 1 |
| Borovkov, NN | 1 |
| Kovaleva, GV | 1 |
| Wen, ZP | 1 |
| Zhang, W | 1 |
| Hu, D | 1 |
| Sun, Y | 1 |
| Liao, Y | 1 |
| Huang, J | 1 |
| Zhao, R | 1 |
| Yang, K | 1 |
| Abdelhady, A | 1 |
| Khader, S | 1 |
| Sinnuqrut, S | 1 |
| Albow, A | 1 |
| Redon, J | 1 |
| Pichler, G | 1 |
| Skoczylas, A | 1 |
| Piecha, G | 1 |
| Więcek, A | 1 |
| Nádházi, Z | 1 |
| Dézsi, CA | 1 |
| Koike, Y | 1 |
| Kawabe, T | 1 |
| Nishihara, K | 1 |
| Iwane, N | 1 |
| Hano, T | 1 |
| Shin, MS | 1 |
| Seo, HS | 1 |
| Park, S | 1 |
| Il Kim, D | 1 |
| Kim, CH | 1 |
| Komuro, I | 1 |
| Shiki, K | 1 |
| Ugai, H | 1 |
| Taniguchi, A | 1 |
| Ikeda, H | 1 |
| Kuroki, D | 1 |
| Nishimura, S | 1 |
| Ogihara, T | 1 |
| Zhong, G | 1 |
| Liu, L | 1 |
| Liu, Y | 1 |
| Yang, L | 1 |
| Luo, Y | 1 |
| Yao, J | 1 |
| Shi, D | 1 |
| Liu, Q | 1 |
| Mourad, JJ | 1 |
| Amodeo, C | 1 |
| Arslan, Z | 2 |
| Ay, SA | 1 |
| Cakar, M | 2 |
| Akhan, M | 1 |
| Sarlak, H | 2 |
| Arslan, E | 1 |
| Demirbas, S | 2 |
| Bulucu, F | 2 |
| Saglam, K | 1 |
| Seyit Ahmet, AY | 1 |
| Naharci, I | 1 |
| Kurt, O | 1 |
| Kocak, N | 1 |
| Bozoglu, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension[NCT04218552] | Phase 2 | 176 participants (Actual) | Interventional | 2020-02-25 | Completed | ||
| A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension[NCT02944734] | Phase 2 | 392 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study[NCT02899455] | Phase 3 | 146 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension[NCT02277691] | Phase 3 | 341 participants (Actual) | Interventional | 2014-11-07 | Completed | ||
| Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by[NCT02738632] | Phase 3 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration[NCT01302691] | Phase 3 | 327 participants (Actual) | Interventional | 2011-01-01 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®] and an Open-label, Long-term Clinical [NCT01299376] | Phase 3 | 286 participants (Actual) | Interventional | 2011-01-24 | Completed | ||
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| [NCT01518998] | Phase 2 | 420 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monother[NCT02152306] | Phase 3 | 143 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in home morning SPB and DBP measured at End of Week 12, End of Treatment (Up to Week 52) relative to baseline. (NCT02277691)
Timeframe: Baseline (End of Run-in Period, Week 0), End of Week 12 and End of Treatment (Up to Week 52)
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Change at End of Week 12, Morning SBP | Change at EOT (Up to Week 52), Morning SBP | Change at End of Week 12, Morning DBP | Change at EOT (Up to Week 52), Morning DBP | |
| TAK-536TCH | -13.9 | -12.4 | -7.9 | -6.9 |
The change in office trough SBP and DBP measured at Weeks 12 last observation was carried forward (LOCF) and 52 (LOCF) relative to baseline. Sitting blood pressure was measured at least 3 times. Each measurement session ended once blood pressure was found stable at 2 consecutive measurements. The average of the last 2 measurements of office sitting blood pressure was used. (NCT02277691)
Timeframe: Baseline (End of Run-in Period, Week 0) and Weeks 12 (LOCF) and 52 (LOCF)
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Change at Week 12 (LOCF), SBP | Change at Week 52 (LOCF), SBP | Change at Week 12 (LOCF), DBP | Change at Week 52 (LOCF), DBP | |
| TAK-536TCH | -14.4 | -13.9 | -8.6 | -8.3 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. (NCT02277691)
Timeframe: Baseline up to Week 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAEs | SAEs | |
| TAK-536TCH | 289 | 20 |
The number of participants with any markedly abnormal clinical laboratory test values collected throughout study. RBC = Red blood cells, ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit. Laboratory vallues were considered abnormal if they were beyond the values defined in categories. (NCT02277691)
Timeframe: Baseline up to Week 52
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RBC (< 0.8×LLN×10^6cells/μL) | Hemoglobin (<0.8 × LLN g/dL) | Hematocrit (<0.8 × LLN Percent) | ALT (>3 × ULN U/L) | AST (>3 × ULN U/L) | Total Bilirubin (>2.0 mg/dL) | Creatinine (>2.0 mg/dL) | Blood Urea Nitrogen (>30 mg/dL) | GGT (>3 × ULN U/L) | Eosinophils (>2 × ULN×10^3cells/μL) | Uric Acid (>13.0 mg/dL) | Total Cholesterol (>300 mg/dL) | Triglycerides (>2.5 × ULN mg/dL) | Potassium (<3.0 mEq/L) | Sodium (<130 mEq/L) | |
| TAK-536TCH | 5 | 2 | 2 | 4 | 4 | 2 | 1 | 20 | 14 | 4 | 1 | 2 | 29 | 3 | 3 |
Vital signs included supine and standing systolic and diastolic blood pressure (SBP and DBP) respectively and office sitting pulse. Vital signs were considered abnormal if they were beyond the values defined in categories. (NCT02277691)
Timeframe: Baseline up to Week 52
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| SBP (Supine) (>180mmHg) | SBP (Standing) (<85mmHg) | SBP (Standing) (>180mmHg) | DBP (Supine) (<50mmHg) | DBP (Standing) (>110mmHg) | Office, Sitting Pulse (<50bpm) | |
| TAK-536TCH | 1 | 1 | 3 | 2 | 4 | 10 |
Reported TEAE is categorized into investigations System Organ Class (SOC) related to body weight. (NCT02277691)
Timeframe: Baseline up to Week 52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Weight decreased | Weight increased | |
| TAK-536TCH | 2 | 2 |
Reported TEAE is categorized into cardiac disorders and investigations system organ class (SOC) related to ECG. (NCT02277691)
Timeframe: Baseline up to Week 52
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Atrial fibrillation | Sinus bradycardia | QRS axis abnormal | |
| TAK-536TCH | 3 | 1 | 1 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -9.1 |
| L50 + A5 | -8.0 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -13.4 |
| L50 + A5 | -10.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 30.5 |
| L50 + A5 | 28.8 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 11.6 |
| L50 + A5 | 3.7 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50 + A5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.6 |
| L50 + A5 | 0.6 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm (NCT01302691)
Timeframe: up to 8 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 1.2 |
| L50 + A5 | 0.0 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -12.1 |
| L50/H12.5 | -6.2 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -17.7 |
| L50/H12.5 | -7.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 27.0 |
| L50/H12.5 | 29.7 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants that experienced at least 1 AE during long-term period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 70.9 |
| L50/H12.5→L50/H12.5/A5 | 66.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 12.1 |
| L50/H12.5 | 14.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the long-term reporting period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 27.7 |
| L50/H12.5→L50/H12.5/A5 | 14.3 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. the percentage of participants that experienced an SAE that assessed as possibly, probably, or definitely related to the study drug by the investigator was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 0.0 |
| L50/H12.5→L50/H12.5/A5 | 0.8 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50/H12.5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Those SAEs assessed as possibly, probably, or definitely related to the study drug during the long-term period were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 3.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week double-blind treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug discontinued during the 44 week extension due to an AE regardless of completion status were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 2.3 |
2 reviews available for amlodipine and Hypertension, Essential
| Article | Year |
|---|---|
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2023 |
The Results of ACES (Antihypertensive Combinations' Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel | 2016 |
44 trials available for amlodipine and Hypertension, Essential
| Article | Year |
|---|---|
Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Coronary Artery Disease; | 2022 |
Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Combi | 2022 |
Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2023 |
Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Essential Hypertension; Hu | 2023 |
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Dyslipid | 2023 |
Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.
Topics: Aged; Amlodipine; Chlorthalidone; Essential Hypertension; Female; Humans; Hypertension; Leukemia, My | 2023 |
Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway.
Topics: Aged; Amlodipine; Animals; Atorvastatin; Essential Hypertension; Humans; Hydroxymethylglutaryl CoA R | 2023 |
The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open-
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadia | 2023 |
Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Cross- | 2020 |
Comparison of Blood Pressure Variability Between Losartan and Amlodipine in Essential Hypertension (COMPAS-BPV).
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Essenti | 2020 |
Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2017 |
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Comorbidity; Do | 2017 |
Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pr | 2018 |
A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension.
Topics: Adult; Aged; Amlodipine; Benzimidazoles; Blood Pressure; Drug Administration Schedule; Drug Therapy, | 2018 |
Effects of triple combination therapy with azilsartan/amlodipine/hydrochlorothiazide on office/home blood pressure: a randomized-controlled trial in Japanese essential hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Double-Blind Method; Drug | 2018 |
Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dizzine | 2018 |
Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring | 2019 |
Efficacy of a new single-pill combination of a thiazide-like diuretic and a calcium channel blocker (indapamide sustained release/amlodipine) in essential hypertension.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; B | 2019 |
A Randomized, Double-blinded, Controlled, Multicentre Phase III Study to Evaluate the Efficacy and Safety of Telmisartan /Amlodipine/Hydrochlorothiazide Compared to Telmisartan/Hydrochlorothiazide in Patients with Essential Hypertension.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Essential Hyperte | 2018 |
[The effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Essential Hypertension; Female; Humans; Hypertensi | 2013 |
Effects of dividing amlodipine daily doses on trough drug concentrations and blood pressure control over a 24-hour period.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cr | 2013 |
Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Bipheny | 2013 |
Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2).
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2014 |
ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis.
Topics: Adult; Aged; Amlodipine; Asian People; ATP Binding Cassette Transporter, Subfamily B; Blood Pressure | 2014 |
The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Anti | 2014 |
Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Drug Combin | 2014 |
Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Dose-Response Relationship, | 2014 |
Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Baroreflex; Blood Pressure; Calcium C | 2014 |
[Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension].
Topics: Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relatio | 2014 |
Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aorta, Th | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Endothelium, Vascula | 2015 |
[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Dose-Response Relationship, D | 2014 |
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Topics: Adult; Aldehyde Oxidoreductases; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2015 |
A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind M | 2015 |
Efficacy and Safety of Fixed-Dose Perindopril Arginine/Amlodipine in Hypertensive Patients Not Adequately Controlled with Amlodipine 5 mg or Perindopril tert-Butylamine 4 mg Monotherapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; D | 2016 |
Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2016 |
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; | 2016 |
The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double- | 2017 |
Effects of Amlodipine and Valsartan on Blood Pressure Variability and Pulse Wave Velocity in Hypertensive Patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Essential Hype | 2017 |
Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2017 |
An additional LDL-lowering effect of amlodipine; not only an antihypertensive?
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C | 2013 |
The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blo | 2013 |
16 other studies available for amlodipine and Hypertension, Essential
| Article | Year |
|---|---|
Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2022 |
Clinical assessment of levamlodipine besylate combination therapy for essential hypertension: A protocol for systematic review and meta-analysis.
Topics: Amlodipine; Combined Modality Therapy; Essential Hypertension; Humans; Meta-Analysis as Topic; Syste | 2022 |
Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteries; Blood Pressure; Diastole; Drug Combinations; Es | 2019 |
The effectiveness of combinated antihypertensive treatment in patients with essential hypertension of the ii-nd stage depending on the type of daily blood pressure profile and the type of remodelling of the left ventricle.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Essentia | 2020 |
Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Essential Hypertension (RESOLVE): A Large, Observational, Retrospective, Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Asian People; Cohort Studies; D | 2020 |
Influence of PRKCH gene polymorphism on antihypertensive response to amlodipine and telmisartan.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Arterial Pressure; Asian People; Benzimidazoles; B | 2017 |
Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; | 2019 |
Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Essential Hyper | 2014 |
Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Dru | 2015 |
[Stiffness of the Arterial Wall and Central Hemodynamics During Long-Term Combination Antihypertensive Therapy].
Topics: Aged; Amlodipine; Antihypertensive Agents; Aorta; Blood Pressure; Drug Combinations; Essential Hyper | 2015 |
[Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinat | 2015 |
Influence of G-protein β-Polypeptide 3 C825T Polymorphism on Antihypertensive Response to Telmisartan and Amlodipine in Chinese Patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Essenti | 2016 |
The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 2016 |
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2016 |
Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Autonomic Nervous System; Azetidinecarboxylic Acid; Blood Press | 2016 |
[Association between gene polymorphism of calcium/calmodulin-dependent kinase 4 and efficacy of amlodipine in the treatment of hypertension in Chinese Han nationality].
Topics: Alleles; Amlodipine; Asian People; Blood Pressure; Calcium-Calmodulin-Dependent Protein Kinase Type | 2016 |